Olvi-Vec
Platinum-Resistant/Refractory Ovarian Cancer
Key Facts
About Genelux
Genelux is a clinical-stage biotech focused on developing oncolytic viral immunotherapies to treat cancer. Its mission is to leverage its proprietary CHOICE™ platform, built on the vaccinia virus backbone, to create therapies that deliver a full complement of tumor neoantigens and stimulate a potent, personalized immune response. The company's strategy centers on advancing its lead candidate, Olvi-Vec, through late-stage trials in ovarian cancer and other solid tumors, while pursuing strategic partnerships and leveraging in-house manufacturing capabilities to build a fully integrated therapeutics company.
View full company profileAbout Genelux
Genelux is a clinical-stage biotech focused on developing oncolytic viral immunotherapies to treat cancer. Its mission is to leverage its proprietary CHOICE™ platform, built on the vaccinia virus backbone, to create therapies that deliver a full complement of tumor neoantigens and stimulate a potent, personalized immune response. The company's strategy centers on advancing its lead candidate, Olvi-Vec, through late-stage trials in ovarian cancer and other solid tumors, while pursuing strategic partnerships and leveraging in-house manufacturing capabilities to build a fully integrated therapeutics company.
View full company profileTherapeutic Areas
Other Platinum-Resistant/Refractory Ovarian Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| Botensilimab + Balstilimab | Agenus | Phase 1/2 |